尿路***癌の骨転移症例に対するDisodium (EHDP)Etidronateの効果検討
スポンサーリンク
概要
- 論文の詳細を見る
Clinical effects of EHDP on relief of bone pain, changes in bone lesions on X-ray and 99mTc-MDP scintigram and performance status were investigated in 19 patients with bone metastasis from urogenital cancers (4 renal cell cancers, 1 renal pelvic cancer, 4 bladder cancers and 10 prostatic cancers). EHDP was effective in relieving bone pain in prostatic cancer patients with osteoblastic lesions. Bone lesions on X-ray and 99mTc-MDP scintigram were slightly improved in prostatic cancer patients with osteoblastic lesions. Administration of EHDP did not improve the performance status. Changes in laboratory data such as serum alkaline phosphatase, serum calcium and urinary total hydroxy-proline following EHDP administration indicated inhibition of osteolytic activity with no effect on bone formation in the early period of treatment (in 4 weeks) and development of both osteolytic activity and bone formation in the later period (from 8 to 12 weeks). No marked side effects were observed. EHDP seems to be effective in relieving bone pain in prostatic cancer patients with osteoblastic bone metastasis. Moreover, some diphosphonate groups including EHDP are expected to be useful to the patients with malignant hypercalcemia.
論文 | ランダム
- 建設デフレーターにおける生産性の問題について
- 最近の産業別生産性の動向--国際比較によるパターンの分析〔昭28〜40〕
- 核戦争は何時起きるか (核戦争をめぐる大学生の主張)
- 「貧困社会」を考える
- 40391 個人差を考慮した居住者の窓開閉行為とクーラー使用に関する基礎的研究(窓・開放感,環境工学I)